Starling Oncology earnings release, May 7, 2026

Starling Oncology, Inc. (DFPH) · Form 8-K, Item 2.02 · Filed · SEC filing

The Oncology Institute Reports First

Quarter 2026 Financial Results

CERRITOS,

Calif., May 7, 2026 -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31,

2026.

Recent

Operational Highlights

First Quarter 2026 Financial Highlights

All comparisons are to the quarter ended

March 31, 2025 unless otherwise noted

Management

Commentary

Daniel Virnich,

CEO of TOI, commented, "The first quarter of 2026 was a strong start to the year for TOI, delivering 41% year over year revenue growth, driven in part by strong capitated revenue growth and a record performance in our pharmacy business. We made meaningful progress on several fronts, including in Florida, where we reached profitability, marking an important milestone that reflects the maturation of our capitated relationships in the state, which is a proof point of our model. Our provider portal, which is designed to underscore our commitment to high quality patient care, strengthen provider engagement, and drive continued adherence to our clinical pathways and quality metrics, is preparing for launch this summer. Looking ahead, we are focused on building on the momentum we have coming out of this quarter, are reaffirming our guidance for 2026 revenue and adjusted EBITDA, and feel confident in our ability to execute sustainable profitability over the long term."

Outlook for Fiscal

Year 2026

TOI uses Adjusted EBITDA and Free Cash flow, each a non-GAAP metric, as an additional tool to assess its operational and financial performance. See "Financial

Information: Non-GAAP Financial Measures" below. In reliance on the unreasonable efforts exception provided under Regulation S-K,

TOI is not reasonably able to provide a quantitative reconciliation for forward-looking information of Adjusted EBITDA and Free Cash flow to net (loss) income and net cash provided by operations, respectively, the most directly comparable GAAP financial measures, without unreasonable efforts due to uncertainties regarding capitated lives, direct costs, taxes, capital expenditures, share-based compensation, change in fair value of liabilities, unrealized (gains) losses on investments, consulting and legal fees, transaction costs and other non-cash items. The variability of these items could have an unpredictable, and potentially significant, impact on TOI’s future

GAAP financial results.

The Company expects approximately $150 million in capitated revenue in 2026. For the second quarter of 2026, we anticipate Adjusted EBITDA of $(1) million to $1 million, reflecting seasonal improvement as deductibles are satisfied and continued ramp of our Florida delegated lives TOI's achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and

Exchange Commission. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating or economic environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings. TOI's outlook assumes a largely stable global market, which would likely be negatively impacted if recent tariff rate increases and exchange rate changes persist and adversely affect world trade.

Webcast and Conference

Call

TOI will host a conference call on Thursday,

May 7, 2026 at 5:30 p.m. (Eastern Time) to discuss first quarter results and management’s outlook for future financial and operational performance.

The conference call can be accessed live over the phone by dialing 1-800-225-9448, or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 11161701. The replay will be available until Thursday, May 21, 2026..

About The Oncology Institute, Inc.

Founded in 2007, The Oncology Institute, Inc. (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 2.0 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Financial statements

Income Statement

2026 Guidance - Previous2026 Guidance - Updated
Revenue$630 to $650 millionUnchanged
Gross Profit$97 to $107 millionUnchanged
Adjusted EBITDA$0 to $9 millionUnchanged
Free Cash Flow$(15) to $5 million$5 to $15 million

Income Statement

Adjusted EBITDA Reconciliation — A reconciliation of net cash flow used in operations to Free Cash Flow and net loss to Adjusted EBITDA, the most comparable GAAP metrics, is set forth below: (in thousands)

Adjusted EBITDA Reconciliation – Three Months Ended March 31, – 2026Adjusted EBITDA Reconciliation – Three Months Ended March 31, – 2025Adjusted EBITDA Reconciliation – Change – $$Adjusted EBITDA Reconciliation – Change – %
Net loss-2,492-19,58517,093-87.3%
Depreciation and amortization1,6161,784-168-9.4%
Interest expense, net1,9345,570-3,636-65.3%
Income tax and other taxes4343
Non-cash addbacks-248-163-8552.1%
Share-based compensation1,6861,45822815.6%
Changes in fair value of liabilities-5,1643,352-8,516-254.1%
Unrealized loss on investments6-6-100.0%
Post-combination compensation expense13-13-100.0%
Consulting fees273332-59-17.8%
Infrastructure and workforce costs-862,124-2,210-104.0%
Adjusted EBITDA-2,438-5,1092,671-52.3%

Income Statement

Three Months Ended March 31, — (in thousands except share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenuePatient services59,08753,068
RevenueSpecialty Pharmacy87,54149,293
RevenueClinical trials & other8132,045
RevenueTotal operating revenue147,441104,406
Operating expensesDirect costs – patient services53,38347,080
Operating expensesDirect costs – specialty pharmacy70,74339,863
Operating expensesDirect costs – clinical trials & other214
Operating expensesSelling, general and administrative expense28,21225,376
Operating expensesDepreciation and amortization1,6161,784
Operating expensesTotal operating expenses153,954114,317
Operating expensesLoss from operations-6,513-9,911
Other non-operating expense (income)Interest expense, net1,9345,570
Other non-operating expense (income)Change in fair value of derivative warrant liabilities-16843
Other non-operating expense (income)Change in fair value of conversion option derivative liabilities-4,9963,309
Other non-operating expense (income)Other, net-791752
Other non-operating expense (income)Total other non-operating expense (income)-4,0219,674
Other non-operating expense (income)Loss before provision for income taxes-2,492-19,585
Other non-operating expense (income)Net loss-2,492-19,585
Other non-operating expense (income)Net loss attributable to common stockholders, basic and diluted-2,094-16,075
Net loss per share attributable to common stockholders:Basic-0.02-0.21
Net loss per share attributable to common stockholders:Diluted-0.02-0.21
Weighted-average number of shares outstanding:Basic101,801,60977,098,825
Weighted-average number of shares outstanding:Diluted101,801,60977,098,825

Balance Sheet

March 31, 2026 — (in thousands except share data)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents30,28033,565
Current assets:Accounts receivable, net58,13458,998
Current assets:Other receivables1,316322
Current assets:Inventories24,29016,875
Current assets:Prepaid expenses and other current assets2,8432,987
Current assets:Total current assets116,863112,747
Current assets:Property and equipment, net10,69710,684
Current assets:Operating right of use assets22,52022,374
Current assets:Intangible assets, net10,30011,015
Current assets:Goodwill7,2307,230
Current assets:Other assets620606
Current assets:Total assets168,230164,656
Current liabilities:Accounts payable47,65043,167
Current liabilities:Current portion of operating lease liabilities7,4047,156
Current liabilities:Accrued expenses and other current liabilities24,29720,639
Current liabilities:Total current liabilities79,35170,962
Current liabilities:Operating lease liabilities18,84319,131
Current liabilities:Derivative warrant liabilities96264
Current liabilities:Conversion option derivative liabilities7,59512,591
Current liabilities:Long-term debt, net of unamortized debt issuance costs78,61177,400
Current liabilities:Other non-current liabilities1928
Current liabilities:Total liabilities184,515180,376
Stockholders’ deficit:Common Stock, 0.0001 par value, authorized 500,000,000 shares; 101,707,558 and 99,973,784 shares issued and outstanding at March 31, 2026 and 100,596,918 shares issued and 98,863,144 shares outstanding at December 31, 20251010
Stockholders’ deficit:Additional paid-in capital258,635256,708
Stockholders’ deficit:Treasury Stock at cost, 1,733,774 shares at March 31, 2026 and December 31, 2025-1,019-1,019
Stockholders’ deficit:Accumulated deficit-273,911-271,419
Stockholders’ deficit:Total stockholders’ equity (deficit)-16,285-15,720
Stockholders’ deficit:Total liabilities and stockholders’ equity (deficit)168,230164,656

Cash Flow

Three Months Ended March 31, — (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Cash flows from operating activities:Net loss-2,492-19,585
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:Depreciation and amortization1,6161,784
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:Amortization of debt issuance costs and debt discount1,2114,874
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:Share-based compensation1,6861,458
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:Change in fair value of liability classified warrants-16843
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:Change in fair value of liability classified conversion option derivatives-4,9963,309
Changes in operating assets and liabilities:Accounts receivable864-985
Changes in operating assets and liabilities:Other receivables-994
Changes in operating assets and liabilities:Inventories-7,415-2,269
Changes in operating assets and liabilities:Prepaid expenses144-1,078
Changes in operating assets and liabilities:Other assets-14-2
Changes in operating assets and liabilities:Accounts payable4,6115,057
Changes in operating assets and liabilities:Change in operating leases-186-162
Changes in operating assets and liabilities:Accrued expenses and other current liabilities3,9182,567
Changes in operating assets and liabilities:Other non-current liabilities1
Changes in operating assets and liabilities:Net cash and cash equivalents used in operating activities-2,215-4,988
Cash flows from investing activities:Purchases of property and equipment-1,042-328
Cash flows from investing activities:Proceeds from asset disposition126
Cash flows from investing activities:Net cash and cash equivalents used in investing activities-1,042-202
Cash flows from financing activities:Proceeds from private placement, net of offering costs15,359
Cash flows from financing activities:Proceeds from employee stock purchase plan220
Cash flows from financing activities:Payments made for financing of insurance payments-260-226
Cash flows from financing activities:Principal payments on long-term debt-20,000
Cash flows from financing activities:Principal payments on financing leases-9-10
Cash flows from financing activities:Common stock issued for options exercised21137
Cash flows from financing activities:Net cash and cash equivalents provided by (used in) financing activities-28-4,740
Cash flows from financing activities:Net decrease in cash and cash equivalents-3,285-9,930
Cash flows from financing activities:Cash and cash equivalents at beginning of period33,56549,669
Cash flows from financing activities:Cash and cash equivalents at end of period30,28039,739
Full release

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private

Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “preliminary,”

“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”

“intend,” “expect,” “should,” “would,” “plan,” “project,” “predict,”

“potential,” “guidance,” “approximately,” “seem,” “seek,” “future,”

“outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, anticipated financial results, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations.

These statements are based on various assumptions and on the current expectations of TOI and are not predictions of actual performance.... (truncated)ly and are not intended to serve as, and must not be relied on by anyone as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of

TOI. These forward-looking statements are subject to a number of risks and uncertainties, including the accuracy of the assumptions underlying the 2026 full fiscal year outlook and the Q2 2026 outlook with respect to Adjusted EBITDA discussed herein, the outcome of judicial and administrative proceedings to which TOI may become a party or investigations to which TOI may become or is subject that could interrupt or limit TOI’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in TOI’s patient or payors' preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet stock exchange listing standards; the impact of a cybersecurity incident affecting a software provider on TOI’s business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC, including the Item 1A. "Risk Factors" section of TOI's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 12, 2026 and any subsequent Quarterly

Reports on Form 10-Q or Current Reports on Form 8-K. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that TOI currently is evaluating or does not presently know or that TOI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect TOI’s plans or forecasts of future events and views as of the date of this press release. TOI anticipates that subsequent events and developments will cause TOI’s assessments to change. TOI does not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing TOI’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Financial Information; Non-GAAP Financial

Measures

Some of the financial information and data contained in this press release, such as Adjusted EBITDA and Free Cash Flow, have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). TOI’s non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial measures determined in accordance with GAAP. Because of the limitations of non-GAAP financial measures, you should consider the non-GAAP financial measures presented in this press release in conjunction with TOI’s financial statements and the related notes thereto.

TOI believes that the use of Free Cash Flow provides an additional tool to assess the Company's financial performance, evaluate its ability to generate cash from operations, and plan for future investments and obligations. Free Cash Flow is useful in understanding the cash available for strategic initiatives. It also helps in comparing TOI's financial performance with other similar companies, many of which use similar non-GAAP financial measures to provide insights into their cash generation capabilities. However, the principal limitation of Free Cash Flow is that it does not account for certain cash outflows or inflows that are required by GAAP to be recorded in TOI's financial statements. TOI defines Free Cash Flow as net cash flow provided by (used in) operations plus cash paid for interest, less capital expenditures.

TOI believes that the use of Adjusted EBITDA provides an additional tool to assess our operations and results of our performance, to plan and forecast future periods, and factors and trends in, and in comparing our financial measures with, other similar companies, many of which present similar non-GAAP financial measures to investors. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in TOI's financial statements.

TOI defines Adjusted EBITDA as net (loss) income plus depreciation, amortization, interest, taxes, non-cash items, share-based compensation, goodwill impairment charges, change in fair value of liabilities, unrealized gains or losses on investments and other adjustments to add-back the following: consulting and legal fees related to acquisitions, one-time consulting and legal fees related to certain advisory projects, software implementations and debt or equity financings, severance expense and temporary labor and recruiting charges to build out our corporate infrastructure.

A reconciliation of net cash flow used in operations to Free Cash Flow and net loss to Adjusted EBITDA, the most comparable GAAP metrics, is set forth below:

Consolidated

Balance Sheets (Unaudited)

(in thousands except share data)

Consolidated Statements of Operations (Unaudited)

(in thousands except share data)

Consolidated

Statements of Cash Flows (Unaudited)

(in thousands)

Media

The Oncology Institute, Inc.

Daniel Virnich, MD danielvirnich@theoncologyinstitute.com

(562) 735-3226 x 81125

Investors

ICR Strategic Communications investors@icrinc.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Starling Oncology earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.